Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Rani Therapeutics Holdings (RANI) Accumulated Depreciation & Amortization (2020 - 2025)

Rani Therapeutics Holdings' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at -$632000.0 for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 54.3% to -$632000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$632000.0, a 54.3% increase, with the full-year FY2025 number at -$632000.0, up 54.3% from a year prior.
  • Accumulated Depreciation & Amortization came in at -$632000.0 for Q4 2025, up from -$1.4 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was -$632000.0 in Q4 2025, with the low at -$4.5 million in Q4 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged -$1.9 million across 5 years, with a median of -$1.5 million in 2021.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: crashed 188.26% in 2023 and later skyrocketed 69.38% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at -$1.5 million in 2021, then fell by 1.56% to -$1.6 million in 2022, then tumbled by 188.26% to -$4.5 million in 2023, then soared by 69.38% to -$1.4 million in 2024, then soared by 54.3% to -$632000.0 in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for RANI at -$632000.0 in Q4 2025, -$1.4 million in Q4 2024, and -$4.5 million in Q4 2023.